Literature DB >> 20673783

A cognitive neuropsychological model of antidepressant drug action.

A Pringle1, M Browning, P J Cowen, C J Harmer.   

Abstract

The psychological mechanisms by which antidepressant drugs act to improve mood remain underspecified. In this paper we consider the evidence to suggest that early changes in emotional processing underlie subsequent mood improvement following antidepressant treatment. Negative biases in information processing are consistently found in depression, and we argue that primary mode of action of antidepressant drugs may be to remediate these biases providing a more positive social environment in which the patient can relearn emotional associations fostering later improvement in mood. Evidence from behavioural and functional magnetic resonance imaging studies supports this hypothesis. Experimental medicine models developed under this premise have the potential to screen for new treatments, to predict individual treatment response and to consider the effects of pharmacological vs psychological treatments.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673783     DOI: 10.1016/j.pnpbp.2010.07.022

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  37 in total

1.  Do changes in trauma-related beliefs predict PTSD symptom improvement in prolonged exposure and sertraline?

Authors:  Andrew A Cooper; Lori A Zoellner; Peter Roy-Byrne; Matig R Mavissakalian; Norah C Feeny
Journal:  J Consult Clin Psychol       Date:  2017-05-15

2.  Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults.

Authors:  Katja Machmutow; Ramona Meister; Alessa Jansen; Levente Kriston; Birgit Watzke; Martin Christian Härter; Sarah Liebherz
Journal:  Cochrane Database Syst Rev       Date:  2019-05-20

3.  Brain Activation During Emotional Memory Processing Associated with Subsequent Course of Depression.

Authors:  Hui Ai; Esther M Opmeer; Dick J Veltman; Nic J A van der Wee; Mark A van Buchem; André Aleman; Marie-José van Tol
Journal:  Neuropsychopharmacology       Date:  2015-04-10       Impact factor: 7.853

4.  Dissociable temporal effects of bupropion on behavioural measures of emotional and reward processing in depression.

Authors:  Annabel E L Walsh; Michael Browning; Wayne C Drevets; Maura Furey; Catherine J Harmer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-03-19       Impact factor: 6.237

Review 5.  Top-Down Control of Serotonin Systems by the Prefrontal Cortex: A Path toward Restored Socioemotional Function in Depression.

Authors:  Collin Challis; Olivier Berton
Journal:  ACS Chem Neurosci       Date:  2015-03-17       Impact factor: 4.418

6.  Abnormal self-schema in semantic memory in major depressive disorder: Evidence from event-related brain potentials.

Authors:  Michael Kiang; Faranak Farzan; Daniel M Blumberger; Marta Kutas; Margaret C McKinnon; Vinay Kansal; Tarek K Rajji; Zafiris J Daskalakis
Journal:  Biol Psychol       Date:  2017-04-03       Impact factor: 3.251

Review 7.  Attentional biases to emotional stimuli: Key components of the RDoC constructs of sustained threat and loss.

Authors:  Brandon E Gibb; John E McGeary; Christopher G Beevers
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2015-09-15       Impact factor: 3.568

8.  Impact of acute administration of escitalopram on the processing of emotional and neutral images: a randomized crossover fMRI study of healthy women.

Authors:  Tim Outhred; Pritha Das; Kim L Felmingham; Richard A Bryant; Pradeep J Nathan; Gin S Malhi; Andrew H Kemp
Journal:  J Psychiatry Neurosci       Date:  2014-07       Impact factor: 6.186

Review 9.  Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis.

Authors:  Y Ma
Journal:  Mol Psychiatry       Date:  2014-03-25       Impact factor: 15.992

Review 10.  Cognitive mechanisms of treatment in depression.

Authors:  Jonathan P Roiser; Rebecca Elliott; Barbara J Sahakian
Journal:  Neuropsychopharmacology       Date:  2011-10-05       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.